Faslodex

Type: Product
Name: Faslodex
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

Different Transcriptional Responses to Fulvestrant  and Estrogen Deprivation in ER-Positive Breast Cancer

By Matthew StengerOctober 15, 2014, Volume 5, Issue 16In a study reported in Clinical Cancer Research , Patani and colleagues investigated whether distinct transcriptional responses were associated with the reported increased effectiveness of the estrogen ... [Published The ASCO Post - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 2 reports

Pfizer's Breast Cancer Candidate Gets Priority Review - Analyst Blog

With the palbociclib NDA being submitted in August this year, a response from the FDA regarding its approval status should be out by Apr 13, 2015. The NDA is based on final results from the phase II PALOMA-1 study.Pfizer is currently conducting two phase ... [Published Nasdaq - Oct 15 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Health Matters: Cabot Principal Doesn't Let Cancer Steal her Passion

CABOT, AR - There is not a dull moment in Tanya Spillane's day.She's the principal at Cabot Freshman Academy overseeing, "777 students in this building and about 85 faculty members."She does it with a smile on her face."That's the best part about this ... [Published KARK TV - Oct 09 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 1 reports

Improvement Engineer -Secondment/Fixed Term Opportunity

DescriptionAstraZeneca's Macclesfield site, located in Cheshire, in the North West of England, is the second largest manufacturing and supply site in the AstraZeneca network. The site is the European Regional packing hub, Global Stability and European ... [Published PharmaDiversity - Oct 07 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Former VP, Oncology, from Pfizer and Otsuka Joins Accelovance to Augment Oncology Growth

ROCKVILLE, Md. -- Accelovance, Inc. (Accelovance), a contract research organization (CRO) focusing in early phase oncology, vaccines, and general medicine, today announced that Dr. Joseph D. Purvis has joined the company as Vice President Medical Affairs, ... [Published Fierce CRO - Oct 06 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

Targeted treatment may be key to metastatic breast cancer patients 'beating the odds'

Eight years ago, Dian Corneliussen-James had surgeons cut out half of her right lung, a risky procedure she believes saved her life.Though she thinks the surgery saved her from death from metastatic breast cancer , which had spread to her lung, she said ... [Published Baltimore Sun - Oct 04 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Roche could lose its dominant market share in breast cancer, says IMS report

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs, such as those from Swiss oncology giant Roche (ROG: SIX), according to a new webinar from IMS Health.Breast Cancer Targeting - Opportunities and Challenges ... [Published Pharma Letter - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Breast cancer drug sales will almost double by 2023, says IMS

Sales of breast cancer treatments are set to increase by an average of 5.8% a year in nine major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to new forecasts from IMS Health. The highest-growing segment ... [Published Pharma Times - Oct 02 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 2 reports

Former VP, Oncology, from Pfizer and Otsuka Joins Accelovance to Augment Oncology Growth

ROCKVILLE, Md."I'm excited to announce Dr. Purvis' addition to our company, his expertise will be invaluable as we continue our growth within early phase oncology," said Stephen TrevisanDr. Purvis brings more than 25 years of oncology drug development ... [Published Stock Nod - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Court Report - September 2014 #6

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Cadence Pharmaceuticals Inc. et al. v. InnoPharma Licensing LLC et al.1:14-cv-01225; filed September 24, 2014 in the District Court of Delaware• Plaintiffs:  ... [Published JD Supra - Sep 29 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Array BioPharma, Inc. (ARRY) Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published FierceBiotech - Sep 19 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Array BioPharma : Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published 4 Traders - Sep 11 2014]

Quotes

"You have a conscious choice everyday to either choose to be a victim"
...his expertise will be invaluable as we continue our growth within early phase oncology," said Stephen Trevisan, Accelovance's President and CEO. "Joe joins Accelovance with an impressive depth and breadth of experience in oncology drug development which he will apply to progress the development goals of our oncology clients."
"We don't know if the cells are just dormant on their own or because of the drug" she said
Infringement of U S Patent Nos. 8,017,615 ( "Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof" issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), and 8,642,760 (same title, issued February 4, 2014) following a Paragraph...

More Content

All (20) | News (18) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Different Transcriptional Responses to Fulvestr... [Published The ASCO Post - Oct 15 2014]
Pfizer's Breast Cancer Candidate Gets Priority ... [Published Nasdaq - Oct 15 2014]
Pfizer's Breast Cancer Candidate Gets Priority ... [Published Zacks.com - Oct 14 2014]
Health Matters: Cabot Principal Doesn't Let Can... [Published KARK TV - Oct 09 2014]
Improvement Engineer -Secondment/Fixed Term Opp... [Published PharmaDiversity - Oct 07 2014]
Former VP, Oncology, from Pfizer and Otsuka Joi... [Published Fierce CRO - Oct 06 2014]
Targeted treatment may be key to metastatic bre... [Published Baltimore Sun - Oct 04 2014]
Roche could lose its dominant market share in b... [Published Pharma Letter - Oct 03 2014]
Breast cancer drug sales will almost double by ... [Published Pharma Times - Oct 02 2014]
Former VP, Oncology, from Pfizer and Otsuka Joi... [Published Stock Nod - Sep 30 2014]
Former VP, Oncology, from Pfizer and Otsuka Joi... [Published InvestorPoint.com - Sep 30 2014]
Court Report - September 2014 #6 [Published JD Supra - Sep 29 2014]
Array BioPharma, Inc. (ARRY) Appoints Victor Sa... [Published FierceBiotech - Sep 19 2014]
Court Report - September 2014 #4 [Published JD Supra - Sep 15 2014]
Array BioPharma : Appoints Victor Sandor, M.D.,... [Published 4 Traders - Sep 11 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer Confirms AstraZeneca Interest [Published The Street Latest - Apr 28 2014]
Pfizer Confirms It Wants To Do A Blockbuster Ta... [Published Clusterstock - Apr 28 2014]
Combination treatment with strontium for the pr... [Published PharmCast - Jan 22 2014]
Higher Dose of Faslodex Effective in Advanced B... [Published BioPortfolio - Dec 30 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 13 2014]
Pfizer Confirms It Wants To Do A Blockbuster Ta... [Published Clusterstock - Apr 28 2014]
Here's a big, juicy M&A story to get the market excited on a Monday morning. Pharmaceutical giant Pfizer has said in a new press release that it has approached UK pharmacuetical maker AstraZeneca about a $100 billion takeover offer, but that AstraZeneca ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.